Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InBody CoXKRX:041830 -3.60%86 FCF Margin % is 8.62% as of Jun. 2026, which is 37% below its 10-year median of 13.68. GuruFocus rates XKRX:041830 with a GF Score™ of 86/100 and a GF Value™ of ₩35,473.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 813 Medical Devices & Instruments companies, InBody Co ranks better than 79.95% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. InBody Co's Free Cash Flow for the
three
months ended in Jun. 2026 was ₩6,316 Mil. InBody Co's Revenue for the
three
months ended in Jun. 2026 was ₩73,254 Mil. Therefore, InBody Co's FCF Margin % for the quarter that ended in Jun. 2026 was 8.62%.
The historical rank and industry rank for InBody Co's FCF Margin % or its related term are showing as below:
XKRX:041830'
s FCF Margin % Range Over the Past 10 Years
Min: -23.32 Med: 13.68 Max: 24.81
Current: 12.54
During the past 13 years, the highest FCF Margin % of InBody Co was 24.81%. The lowest was -23.32%. And the median was 13.68%.
XKRX:041830's FCF Margin % is ranked better than 79.95% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: -0.52
vs XKRX:041830: 12.54
The historical data trend for InBody Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:041830 vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, InBody Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InBody Co FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InBody Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where InBody Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InBody Co (XKRX:041830) has a FCF Margin % of 8.62% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on InBody Co and its competitors. This is 37% below median its historical median of 13.68. According to the industry distribution chart, InBody Co ranks #163 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 20%.
Is InBody Co's FCF Margin % too high?
InBody Co's current FCF Margin % of 8.62% is 37% below median its 10-year median of 13.68. Based on the distribution chart, InBody Co ranks #163 out of 813 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InBody Co has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InBody Co's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, InBody Co ranks #163 out of 813 companies for FCF Margin %. This places InBody Co in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on InBody Co and its competitors. InBody Co's current FCF Margin % is 8.62%, which is 37% below median its own 10-year median of 13.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InBody Co stock overvalued right now?
Based on GuruFocus' analysis, InBody Co (XKRX:041830) is currently considered Significantly Overvalued. The stock's GF Value™ is ₩35,473.99, compared to a current price of ₩58,900.00 — trading 66% above its estimated fair value. The current FCF Margin % is 8.62%, which is 37% below median its 10-year median of 13.68. InBody Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For InBody Co (XKRX:041830), the current FCF Margin % is 8.62% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InBody Co (XKRX:041830) Overvalued in 2026?
Based on GuruFocus' analysis, InBody Co stock appears to be overvalued.
The current stock price of ₩58,900.00 is trading 66% above its estimated GF Value™ of ₩35,473.99.
GuruFocus considers InBody Co to be Significantly Overvalued.
Key valuation signals for XKRX:041830:
FCF Margin %: 8.62% (37% below median its 10-year median of 13.68)
GF Value™: ₩35,473.99 vs. price of ₩58,900.00 (66% above fair value)
No single metric tells the full story. See the XKRX:041830 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InBody Co Ltd is a Korea-based company engaged in the manufacturing and distribution of body composition analyzers. The company mainly produces body composition analyzers under the brand name InBody and Lookin'Body. It's InBody series products include InBody720, InBody570, InBody230, InBody J30, and InBody S10.
86GF Score
Get the complete analysis for XKRX:041830
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:041830 has been successfully added to your 
